Robert Grubb to Mass Screening
This is a "connection" page, showing publications Robert Grubb has written about Mass Screening.
Connection Strength
0.764
-
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
Score: 0.207
-
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
Score: 0.103
-
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
Score: 0.064
-
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61.
Score: 0.059
-
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
Score: 0.053
-
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
Score: 0.050
-
The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
Score: 0.048
-
Results of compliance with prostate cancer screening guidelines. J Urol. 2005 Aug; 174(2):668-72; discussion 672.
Score: 0.041
-
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
Score: 0.040
-
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8.
Score: 0.040
-
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2241-9.
Score: 0.018
-
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
Score: 0.017
-
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51.
Score: 0.013
-
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
Score: 0.011